Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial

Leuk Lymphoma. 2019 Sep;60(9):2291-2294. doi: 10.1080/10428194.2019.1576870. Epub 2019 Feb 18.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Comparative Study
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alemtuzumab / administration & dosage
  • Alemtuzumab / adverse effects*
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Humans
  • Incidence
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / immunology
  • Lymphoma, T-Cell / mortality
  • Maximum Tolerated Dose
  • Middle Aged
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Progression-Free Survival
  • Survival Rate
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Virus Activation / drug effects
  • Virus Activation / immunology
  • Virus Diseases / chemically induced
  • Virus Diseases / epidemiology*
  • Virus Diseases / immunology

Substances

  • Antineoplastic Agents, Immunological
  • Alemtuzumab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol

Associated data

  • ClinicalTrials.gov/NCT00562068